En general, los resultados de este estudio, que sigui a ms de 200.000 personas con diabetes tratadas con GLP1RAs y las compar con ms de 1,5 millones de personas bajo otros tratamientos para la diabetes, son tranquilizadores en cuanto a la relacin riesgo/beneficio del uso a largo plazo de GLP1RAs en personas con diabetes
Retatrutide, with its triple-receptor action, may offer greater weight loss for some individuals, while tirzepatide has also demonstrated strong results
Which one is right for you will depend on your lifestyle, financial means, and even your GLP-1 dosage
It reflects three completely different products being sold under the same name, in three different markets, with three different levels of medical oversight
however, trials are investigating the agent in type 2 diabetes and obesity